Journals / Klimik Dergisi / 2018 / Cilt: 31 - Sayı: 2

Bacteriophage Therapy: An Unforgetten Source of Cure

Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı

Pages
78–87
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Klimik Dergisi. 2018; 31(2): 78-87.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multidrug resistance observed in microorganisms, especially in hospital-based pathogens, poses a serious public health threat.
📊
Key Findings & Data:Although bacteriophage (phage) therapy was quite popular between 1920 and 1950, it has been abandoned in many parts of the world due to various reasons, nowadays it is again at the agenda and is at the forefront of alternative therapies.
💡
Conclusion & Impact:Klimik Dergisi. 2018; 31(2): 78-87.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Multidrug resistance observed in microorganisms, especially in hospital-based pathogens, poses a serious public health threat. While scientists have not been able to develop a radical solution for the increasing antibiotic resistance problem, the search for treatment alternatives in appropriate clinical settings continues consistently. Although bacteriophage (phage) therapy was quite popular between 1920 and 1950, it has been abandoned in many parts of the world due to various reasons, nowadays it is again at the agenda and is at the forefront of alternative therapies. In this rediscovery process in area of infectious diseases and clinical microbiology, it is important to consider the interesting history of phage therapy, the reasons for abandonment, the advantages/ disadvantages over antibiotics, and the concerns about deployment in clinical use. Klimik Dergisi. 2018; 31(2): 78-87.

Özet

Hastane kökenli patojenler başta olmak üzere, mikroorganizmalardagörülen çoklu antibiyotik direnci halk sağlığı için ciddibir tehdit oluşturmaktadır. Bilim insanları, artan antibiyotik direncigelişimine radikal bir çözüm getiremezken, uygun klinikdurumlarda tedavi alternatifleri arayışı hızla devam etmektedir.Bakteriyofaj (faj) terapisi 1920-1950 yılları arasında oldukçapopüler olmasına rağmen, çeşitli sebeplerle dünyanın büyükbir kısmında terk edilen ve bugün tekrar hatırlanan bir yöntemolarak alternatif terapilerin başında yer almaktadır. İnfeksiyonhastalıkları ve klinik mikrobiyoloji alanındaki bu yeniden keşifsürecinde, faj terapisinin ilginç tarihi, terk edilme sebepleri,antibiyotiklere göre üstünlükleri/zayıflıkları ve yeniden klinikkullanıma girmesiyle ilgili kaygılar hakkındaki bilgilerin gözdengeçirilmesi önem taşımaktadır.Klimik Dergisi. 2018; 31(2): 78-87.

🔖

Cite This Article

GÜNDOĞDU, A., KILIÇ, A. U. (2022). Bacteriophage Therapy: An Unforgetten Source of Cure. Klimik Dergisi, Cilt: 31 - Sayı: 2, 78–87. https://ajindex.com/articles/573485

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sulakvelidze A, Alavidze Z, Morris JG-Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001
  2. 45(3): 649-59. [CrossRef] 2. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010
  3. 28(12): 591-5. [CrossRef] 3. Hankin EH. L’action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur. 1896
  4. Twort FW. An investigation on the nature of ultramicroscopic viruses. Lancet. 1915
  5. 186(4814): 1241-3. [CrossRef] 5. Summers WC. Félix d'Herelle and the Origins of Molecular Biology. New Haven, Conn: Yale University Press, 1999. 6. Fruciano DE, Bourne S. Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West. Can J Infect Dis Med Microbiol. 2007
  6. 18(1): 19-26. [CrossRef] 7. d’Hérelle F. Essai de le traitement de la peste bubonique par le bactériophage. Presse Méd. 1925
  7. Compton A. Results of bacteriophage treatment of bacillary dysentery at Alexandria. A statistical retrospect. BMJ. 1942
  8. i(4249): 719-20. [CrossRef] 9. Summers WC. Bacteriophage therapy. Annu Rev Microbiol. 2001
  9. [CrossRef] 10. Himmelweit F. Combined action of penicillin and bacteriophage on Staphylococci. Lancet. 1945
  10. 246(6361): 104-5. [CrossRef] 11. Eaton MD, Bayne-Jones S. Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA.1934
  11. 103(23):1769-939. [CrossRef] 12. Krueger AP, Scribner EJ. Bacteriophage therapy. II. The bacteriophage: its nature and its therapeutic use. JAMA. 1941
  12. 116(19): 2160–67. [CrossRef] 13. d’Herelle F. Les Pérégrinations d’un Microbiologiste. Paris: Archives de l’Institute Pasteur, 1946 (Yayımlanmamış taslak). 14. Monsur KA, Rahman MA, Hug F, Islam MN, Northrup RS, Hirschhorn N. Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bull World Health Organ. 1970
  13. 42(5): 723-32. 15. Witting HJ, Raffetto JF, Bason R. Bacteriophage therapy in infective childhood asthma. JAMA. 1966
  14. 196(5): 435. [CrossRef] 16. Brüssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev. 2004
  15. 68(3): 560-602. [CrossRef] 17. Letkiewicz S, Międzybrodzki R, Kłak M, Jończyk E, Weber- Dąbrowska B, Górski A. The perspectives of the